Patients in the PEACE trial were at lower risk and were receiving more aggressive secondary prevention therapy than those in the HOPE trial. In ALLHAT,96 in which 25% of participants had CAD, there were no significant differ- ences among patients taking chlorthalidone, amlodipine, and lisinopril in the combined outcomes of fatal CAD and nonfa- tal MI (the primary outcome of the study), in combined CAD (the primary outcome plus coronary revascularization or hos- pitalization for angina), or in all-cause mortality. Soon after the ALLHAT results were published, the Second Australian National Blood Pressure Study (ANBP-2) reported the results of a prospective, open-label study in patients 65 to 84 years of age with hypertension that showed, in men but not in women, better cardiovascular outcomes with ACE inhibitors than with diuretic agents despite similar reductions in BP.175 4.1.4. Angiotensin Receptor Blockers ARBs are recommended for all patients with stable angina who also have hypertension, diabetes mellitus, LV ejection fraction 40%, or CKD and have indications for, but are intol- erant of, ACE inhibitors (Class I; Level of Evidence A).169 ARBs are indicated during hospitalization and at discharge for STEMI patients who are intolerant of ACE inhibitors and have HF or an ejection fraction <0.40 (Class I; Level of The combination of ACE inhibitors and ARBs has been used for the treatment of advanced or persistent HF in the convalescent or chronic phase after STEMI,177 but the failed to show additive benefit but with a substantial increase in side effects, so this combination is not recommended. 